Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.380
+0.382 (38.26%)
At close: Apr 2, 2025, 4:00 PM
2.010
+0.630 (45.67%)
After-hours: Apr 2, 2025, 5:17 PM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
2.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
APVO News
- 13 days ago - RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment - Accesswire
- 15 days ago - Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy - Accesswire
- 27 days ago - Aptevo to Participate in March Conferences - Accesswire
- 6 weeks ago - Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 6 weeks ago - Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - Accesswire
- 2 months ago - Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - Accesswire
- 3 months ago - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Accesswire
- 3 months ago - 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - Accesswire